Categories: News

TE Connectivity to report fourth quarter and full year financial results on October 30, 2024

GALWAY, Ireland, Oct. 9, 2024 /PRNewswire/ — TE Connectivity plc (NYSE: TEL) will report financial results for the fourth quarter and full year of fiscal 2024 before trading begins on October 30, 2024. The company will hold a conference call for investors at 8:30 a.m. ET. The conference call may be accessed in the following ways:

  • At TE Connectivity’s website: investors.te.com  
  • By telephone: For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the United States is (800) 715-9871 and for international callers, the dial-in number is (646) 307-1963
  • A replay of the conference call will be available on TE Connectivity’s investor website at investors.te.com at 11:30 a.m. ET on October 30, 2024.

ABOUT TE CONNECTIVITY
TE Connectivity plc (NYSE: TEL) is a global industrial technology leader creating a safer, sustainable, productive, and connected future. Our broad range of connectivity and sensor solutions enable the distribution of power, signal and data to advance next-generation transportation, renewable energy, automated factories, data centers, medical technology and more. With more than 85,000 employees, including 8,000 engineers, working alongside customers in approximately 140 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat, Instagram and X (formerly Twitter). 

View original content to download multimedia:https://www.prnewswire.com/news-releases/te-connectivity-to-report-fourth-quarter-and-full-year-financial-results-on-october-30-2024-302271235.html

SOURCE TE Connectivity plc

Staff

Recent Posts

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…

1 hour ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…

1 hour ago

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…

1 hour ago

A Christmas Message to the DEA’s Diversion Anti Marijuana Cabal

This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally…

4 hours ago

Kanazawa University research: High-speed AFM imaging reveals how brain enzyme forms dodecameric ring structure

KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa…

10 hours ago

Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…

16 hours ago